Symptom improvement with BDP/FF/G fixed triple inhalation powder in moderate to severe COPD patients uncontrolled with dual therapies

Résumé fourni par la source

People living with COPD are frequently inadequately treated due to underdiagnosis ormisdiagnosis. The aim of this study was to evaluate the real-world performance of thebeclomethasone dipropionate/formoterol fumarate/glycopyrronium (BDP/FF/G) fixed triplecombination formulated in a dry powder inhaler (DPI) in improving symptoms, lungfunction, and adherence in moderate to severe COPD patients uncontrolled on dualtherapies. We conducted a non-interventional, open-label, single-arm, multicenter,prospective study across 19 outpatient centers in Slovenia. The primary objective was tomeasure symptom improvement with the COPD Assessment Tool (CAT). A total of 359patients with moderate to severe COPD (97% classified as GOLD E, frequent exacerbators)were followed for 24 weeks. There was a significant 6-point reduction in the CAT score afterswitching from dual therapies to BDP/FF/G inhalation powder (95% CI: −7.0 to −5.5

Ce résumé expose les affirmations des auteurs. BNTIC ne l’interprète pas comme une validation indépendante des résultats.